BSX slides nearly 5% as earnings disappoint and long-term technicals remain bearish

Traders Union
All News
Stocks
Boston Scientific slides 4.87% today

Highlights

Boston Scientific reported Q3 2026 revenue of $5.14 billion, up about 1.4 to 1.5% year over year.
The company matched EPS consensus at $0.73 and started a restructuring plan aiming for over $500 million in cost savings.
Shares of Boston Scientific last traded at $42.88, with a bearish technical setup and a projected five-day range of $38.77 to $43.65.

Sales outlook cut and restructuring accelerate negative sentiment despite mixed earnings

Boston Scientific reported Q3 2026 revenue of approximately $5.14 billion, marking a year-over-year increase of about 1.4-1.5%. Earnings per share matched consensus at $0.73, but fell short of the $0.75 from the prior year. The company lowered its full-year sales outlook and cited ongoing challenges from a cybersecurity incident and weakness in its electrophysiology business, while initiating a restructuring program targeting over $500 million in cost savings over three years.

Anton Kharitonov, expert at Traders Union, sees Boston Scientific’s performance as deeply concerning. He points out the persistent technical weakness, with prices below all major moving averages, showing a clear bearish trend. The decline in profit and the lowered sales guidance signal ongoing operational issues. The restructuring program may support future margins, but near-term sentiment remains pressured by unresolved cybersecurity concerns. "Until the company addresses both its internal weaknesses and external challenges, I see little reason for optimism here."

Viktoras Karapetjanc, expert at Traders Union, maintains a constructive view despite recent setbacks. He believes Boston Scientific’s modest revenue growth and decisive restructuring show the company’s commitment to restoring profitability. Market sentiment may be cautious, but the cost reduction plan unlocks future upside opportunities. Karapetjanc notes that leadership’s quick response to operational challenges reflects a resilient business model. "With these strategic efforts, I expect Boston Scientific to regain investor confidence and return to a growth trajectory."

Parshwa Turakhiya, analyst, views the current setup as volatile but full of short-term trading potential. He notes mixed signals from momentum indicators, with buyers showing strength but trend direction still unclear. Recent recovery from intraday lows suggests active sentiment-driven trading opportunities. Turakhiya advises focusing on key price levels for tactical plays. "Traders should watch $43.65 and $38.77 as trigger points for the next decisive move."

Bearish trend persists as momentum signals diverge near key technical levels

Boston Scientific is trading below its 20-day, 50-day, and 200-day moving averages at $43.83, $45.29, and $57.3, respectively, underscoring short-, medium-, and long-term downward pressure. The nearest resistance is at $43.65, and initial support is located at $39.72. The long-term trend remains bearish due to the alignment of the 50-day below the 200-day average. Momentum indicators are mixed: the MACD signals a buy, while the ADX remains neutral, suggesting uncertainty in trend conviction. The RSI and CCI present buy signals, which point to the absence of oversold risk. Stochastic RSI is neutral, and the Bull/Bear Power at 0.63 shows buyers leading intraday momentum, though it is in overbought territory. Intraday action displayed some recovery after an early gap down, but momentum readings diverge, highlighting indecision.

Earlier, analysts noted that Boston Scientific faced continuing operational headwinds and a sustained bearish technical outlook following the impact of a cybersecurity incident and cautious forward guidance. The current article reinforces this perspective, highlighting that despite recent intraday recovery attempts, consolidation below key resistance levels remains the prevailing scenario, with traders advised to monitor $43.65 for potential shifts in momentum.

Source of Data: BSX Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.